Health Care Facilities

PACS

PACS released FY2026 Q1 earnings on May 11 After-Market EST, actual revenue USD 1.42 B (forecast USD 1.364 B), actual EPS USD 0.5 (forecast USD 0.3971)

PACS to Release FY2026 Q1 Earnings on May 11 After-Market EST, Forecast Revenue USD 1.364 B, EPS USD 0.3971

PACS released FY2025 Q4 earnings on February 26 After-Market EST, actual revenue USD 1.358 B (forecast USD 1.383 B), actual EPS USD 0.3753 (forecast USD 0.4688)

PACS released FY2025 Annual Earnings on February 26 After-Market (EST), actual revenue USD 5.289 B (forecast USD 5.314 B), actual EPS USD 1.22 (forecast USD 1.4779)

PACS Group CEO to Speak at J.P. Morgan Healthcare Conference

RBC Capital analyst maintains buy rating on PACS Group Inc

PACS Group Inc. revised its credit agreement to ease cash holding restrictions

PACS Group Inc. Director Evelyn S. Dilsaver Buys Company Stock

PACS Group Reports Strong Earnings, Raises Full-Year Revenue Guidance

RBC Raises PACS Group's Target Price

PACS released FY2025 Q3 earnings on November 19 (EST), actual revenue USD 1.345 B (forecast USD 1.158 B), actual EPS USD 0.3199 (forecast USD 0.47)

PACS released FY2023 Q4 earnings on November 19 (EST), actual revenue USD 853.2 M, actual EPS USD 0.2651

PACS released FY2025 9 Months earnings on November 19 (EST), actual revenue USD 3.931 B, actual EPS USD 0.7999

PACS released FY2025 Q1 earnings on November 19 (EST), actual revenue USD 1.277 B (forecast USD 1.093 B), actual EPS USD 0.17 (forecast USD 0.42)

PACS released FY2025 Q2 earnings on November 19 (EST), actual revenue USD 1.309 B (forecast USD 1.157 B), actual EPS USD 0.3099 (forecast USD 0.48)

PACS released FY2024 Q4 earnings on November 19 (EST), actual revenue USD 1.208 B (forecast USD 1.071 B), actual EPS USD 0.2388 (forecast USD 0.4)

PACS released FY2023 Q3 earnings on November 19 (EST), actual revenue USD 789.19 M, actual EPS USD 0.15

PACS released FY2024 annual earnings on November 19 (EST), actual revenue USD 4.09 B (forecast USD 3.938 B), actual EPS USD 0.3799 (forecast USD 1.03)

PACS released FY2025 Semi-Annual Earnings on November 19 (EST), with actual revenue of USD 2.586 B and EPS of USD 0.48

PACS released FY2024 9 Months Earnings on November 19 After-Market EST, Actual Revenue: USD 2.882 B, Actual EPS: USD 0.1567

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Yesterday, PACS's stock price surged by 28.56%, closing at $41.01, with a trading volume of approximately $144 million, indicating a significant influx of capital in a short period. The MACD daily line established a bullish signal above the zero axis, combined with such a strong single-day performance, the technical indicators show an impulsive surge in buying power. During the trading session, the stock exhibited strong momentum, maintaining a high price range for most of the time, indicating limited selling pressure and strong control by the bulls. For a healthcare stock, a nearly 30% increase in a single day is considered an unconventional anomaly. On the news front, the healthcare industry, where PACS operates, has recently attracted dual attention from policies and the capital market. UnitedHealth (UNH) also rose by 3.11% on the same day, while the healthcare ETF (XLV) increased by 1.96%, with active capital inflow across the entire healthcare sector. In an environment of rising inflation and pressured consumer spending, the defensive attributes of healthcare as a necessity industry are being repriced by the market. PACS, as an operator focused on postoperative care and rehabilitation services, has an attractive stable cash flow model in a high-interest-rate environment. There may be positive catalysts at the company level, such as better-than-expected earnings reports or business expansion, driving this aggressive upward trend. Technically, the nearly 30% surge in a single day has pushed the stock price far from the short-term moving average system, leading to a rapid accumulation of short-term profit-taking. The effectiveness of the $40 integer level turning from overhead resistance to support needs to be validated in subsequent trading days

Technical Forecast

Unitedhealth

SPDR S&P Health Equip

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

iShares Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares US Healthcare Providers

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Invesco Biotechnology & Genome ETF

SPDR S&P Health

iShares US Medical Devices

VG Health

Leverage Shares 2X Long UNH Daily ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Pre-market trend | PACS (PACS) surged nearly 29% on 5/12, attracting attention to the rise of healthcare stocks?

AMBQ

VSTS

AEVA

QUBT

AVEX

Ambiq Micro(AMBQ) rose 45.33%, with a trading turnover 182.3 Million USD, and a year-to-date rose 132.9%. Rackspace Tech(RXT) rose 34.97%, with a trading turnover 324.9 Million USD, and a year-to-date rose 552%. Vestis(VSTS) rose 29.03%, with a trading turnover 112.7 Million USD, and a year-to-date rose 79.9%.

Top Gainers&Losers

Ambiq Micro

Rackspace Tech

Vestis

Vishay Precision

Aeva Tech

Ralliant

Wendys

Quantum Computing

Aevex

Top 10 US Stock Gainers (5.12)

SMTI

ATYR

ERNA

USBC

In Tuesday's intraday session, Ernexa Therapeutics (NASDAQ:ERNA) saw a significant gain of 79.4%, reaching $12.94, while USBC (AMEX:USBC) rose by 55.72% to $0.79. Other notable gainers included Sanara MedTech (NASDAQ:SMTI) up 30.21%, and PACS Group (NYSE:PACS) up 26.47%. Conversely, Tyr Pharma (NASDAQ:ATYR) experienced a decline of 27.4%, followed by CEL-SCI (AMEX:CVM) down 25.89%. The Q1 earnings reports for several companies were released yesterday, impacting stock movements.

benzinga_article

Sanara Medtech

ATYR Pharma

Ernexa Therapeutics

CEL-SCI

Direxion S&P Biotech Bear 3X

Invesco Nasdaq Biotechnology ETF

Alpha Compute

Macrogenics

WORK Medical Tech

Akari Therap

CVRx

Harrow

Harrow Health Pref Share HROWM 11.875 12/31/27

Harrow Health Pref Share HROWL 8.625 04/30/26

12 Health Care Stocks Moving In Tuesday's Intraday Session

PACS Group (NYSE:PACS) reported Q1 2026 revenue of $1.42 billion, an 11% year-over-year increase, with a net income of $80.7 million. The company operates 323 facilities across 17 states, focusing on operational consistency and strategic growth. PACS increased its adjusted EBITDA guidance for 2026 to $605 million-$625 million, driven by strong performance. Key operational highlights include high occupancy rates and improved clinical outcomes. Management emphasized ongoing investments in leadership development and infrastructure to maintain high-quality care and support growth.

Full Transcript: PACS Group Q1 2026 Earnings Call

GTLB

US equity futures and bonds fell as oil prices rose, driven by a key inflation report indicating higher energy costs and supply disruptions from the Iran conflict. The core CPI increased more than expected, leading to declines in major tech stocks and chipmakers. In premarket trading, all major tech stocks were down, with significant losses for AST SpaceMobile, GameStop, and GitLab. Conversely, PACS Group and Quantum Computing saw substantial gains. The economic data slate includes ADP employment change and April CPI, while Fed speakers are scheduled throughout the day.

- US equity futures and bonds declined as oil prices rose, influenced by a key inflation report reflecting high energy costs and supply chain disruptions from the Iran war.  
- The core CPI increased 2.8% in April, surpassing expectations, leading to anticipated decreases in stock prices from historical highs, particularly affecting major tech firms.  
- As geopolitical tensions continue to affect markets, upcoming economic data releases are expected to further inform investor sentiment and central bank responses.

ZeroHedge

Occidental Petroleum

GitLab

GameStop

AST SpaceMobile

VG Energy

SPDR O&G Equip

ISHRS S&P Glb Engy

iShares US Oil & Gas Expl & Prod

SPDR O&G Ex & Prd

iShares US Oil Equip & Svcs

SPDR Energy Select

VanEck Oil Services ETF

VanEck Oil Refiners ETF

ProShares Ultra Energy

T-Rex 2X Long GME Daily Target ETF

Pro Ultr Bloomberg Crude Oil

Bosera S&P 500 ETF

Guotai S&P 500 ETF(QDII)

S&P 500

SPDR S&P 500

Mitsubishi UFJ Financial Group, Inc.

Pacer Cash COWZ 100-Nasdaq100RotatorETF

NASDAQ-100

Kaspi.KZ JSC

Koss

Kopin

Tesla

Alphabet

Alphabet - C

Amazon

NVIDIA

Microsoft

Meta Platforms

Apple

eBay

Harmonic

Hims & Hers Health

iHeartMedia

Microvast

Plug Power

Walmart

Power Solutions

Venture Global

TotalEnergies SE

Vital Farms

Vital Energy

Vitasoy

Nano Labs

Webtoon ENT

Trinity Capital

Jupiter Fund Management plc

TriLinc Global Impact Fund, LLC

ZoomInfo Tech

JPMorgan Chase

NVIDIA Corporation

GAMESTOP CORPORATION C/WTS (TO PUR COM) 30/10/2026

Microvast Holdings - CW26

Plug Power Inc.

Trinity Capital Pref Share TRINL 7 01/16/25

TRINITY CAPITAL INC 7.875% NTS 30/09/2029

TRINITY CAPITAL INC 7.875% NOTES DUE 2029

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Stocks Fall, Oil And Rates Rise As Inflation "Roars Back"

MGNX

In Tuesday's pre-market session, PACS Group saw a significant gain of 17.6%, reaching $37.5, with a market cap of $5.0 billion. Other notable gainers included Akari Therapeutics (+16.31%), Macrogenics (+16.27%), and USBC (+12.69%). Conversely, WORK Medical Tech experienced a sharp decline of 45.7%, followed by CEL-SCI (-26.25%) and Pomdoctor (-22.69%). Overall, the session highlighted substantial movements in health care stocks, influenced by recent earnings reports.

Pomdoctor

Phio Pharmaceuticals

Dyadic

China Pharma

Organigram

Ensysce Biosciences

Ensysce Biosciences - CW22

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

ABCL

In Monday's after-market session, PACS Group shares surged 15.4% to $36.8 following its Q1 earnings report, with a market cap of $5.2 billion. Other gainers included BioVie (+7.4%), GT Biopharma (+7.29%), and AbCellera Biologics (+7.04%). Conversely, WORK Medical Tech saw the largest decline at -27.6%, followed by Ensysce Biosciences (-14.04%) and aTyr Pharma (-12.65%).

Abcellera Biologics

Biovie

GT Biopharma

P3 Health Partners

Advanced Biomed

Odysight.ai

BIOVIE INC C/WTS 08/08/2030(TO PUR COM)

P3 HEALTH PARTNERS INC C/WTS 19/11/2026 (TO PUR COM)

12 Health Care Stocks Moving In Monday's After-Market Session

PACS Group shares are trading higher after the company reported better-than-expected Q1 financial results. Also, the company announced a $250 million share buyback.

PACS(PACS.US)